{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:15:40Z","timestamp":1792790140722,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.semarthrit.2022.152058","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T01:58:14Z","timestamp":1656467894000},"page":"152058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-7353","authenticated-orcid":false,"given":"Sizheng Steven","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skanda","family":"Rajasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Karhunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uazman","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipender","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152058_bib0001","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/art.41404","article-title":"Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990\u20132017: a systematic analysis of the global burden of disease study 2017","volume":"72","author":"Safiri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0002","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007\u20132008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0003","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0004","doi-asserted-by":"crossref","first-page":"186","DOI":"10.7326\/M19-2610","article-title":"Assessing the risk for gout with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a population-based cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0005","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/pds.5252","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis","volume":"30","author":"Lund","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0006","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35353","article-title":"Association of sodium-glucose transport protein 2 inhibitor use for type 2 diabetes and incidence of gout in Taiwan","volume":"4","author":"Chung","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0007","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","article-title":"The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS program","volume":"1","author":"Li","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0008","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-018-1746-1","article-title":"Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study","volume":"20","author":"Roughley","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0009","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0010","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0011","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0012","doi-asserted-by":"crossref","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","article-title":"Mendelian randomization for studying the effects of perturbing drug targets","volume":"6","author":"Gill","year":"2021","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0013","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1093\/hmg\/ddu328","article-title":"Mendelian randomization: genetic anchors for causal inference in epidemiological studies","volume":"23","author":"Davey Smith","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0014","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet N Am Ed"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0016","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10654-018-0424-6","article-title":"Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates","volume":"33","author":"Burgess","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0017","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41588-021-00852-9","article-title":"The trans-ancestral genomic architecture of glycemic traits","volume":"53","author":"Chen","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0018","unstructured":"NealeLab. Rapid GWAS of thousands of phenotypes for 337,000 samples in the UK Biobank. 2020 [accessed 2020 Jun 16]. Available from: http:\/\/www.nealelab.is\/uk-biobank."},{"key":"10.1016\/j.semarthrit.2022.152058_bib0019","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/s41588-019-0504-x","article-title":"Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels","volume":"51","author":"Tin","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0020","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/gepi.21758","article-title":"Mendelian randomization analysis with multiple genetic variants using summarized data","volume":"37","author":"Burgess","year":"2013","journal-title":"Genet Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0021","first-page":"362","article-title":"Reading Mendelian randomization studies: a guide, glossary, and checklist for clinicians","author":"Davies","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0022","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/ije\/dyr036","article-title":"Avoiding bias from weak instruments in Mendelian randomization studies","volume":"40","author":"Burgess","year":"2011","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0023","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","article-title":"Genetic variants in SGLT1, glucose tolerance, and cardiometabolic risk","volume":"72","author":"Seidelmann","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0024","article-title":"The MR-Base platform supports systematic causal inference across the human phenome","volume":"7","year":"2018","journal-title":"eLife"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152058_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004383","article-title":"Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics","volume":"10","author":"Giambartolomei","year":"2014","journal-title":"PLoS Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0026","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0027","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0028","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0029","doi-asserted-by":"crossref","first-page":"F173","DOI":"10.1152\/ajprenal.00462.2018","article-title":"SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1","volume":"316","author":"Novikov","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0030","doi-asserted-by":"crossref","first-page":"E831","DOI":"10.1152\/ajpendo.00296.2009","article-title":"Facilitative glucose transporter 9, a unique hexose and urate transporter","volume":"297","author":"Doblado","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0031","doi-asserted-by":"crossref","first-page":"6791","DOI":"10.1038\/s41598-018-25054-y","article-title":"High basolateral glucose increases sodium-glucose cotransporter 2 and reduces sirtuin-1 in renal tubules through glucose transporter-2 detection","volume":"8","author":"Umino","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0032","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12020-016-0896-7","article-title":"SIRT1 prevents hyperuricemia via the PGC-1\u03b1\/PPAR\u03b3-ABCG2 pathway","volume":"53","author":"Wang","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0033","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ncomms1756","article-title":"Decreased extra-renal urate excretion is a common cause of hyperuricemia","volume":"3","author":"Ichida","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0034","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s10157-013-0806-8","article-title":"Uric acid transporter ABCG2 is increased in the intestine of the 5\/6 nephrectomy rat model of chronic kidney disease","volume":"18","author":"Yano","year":"2014","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0035","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1080\/13880209.2016.1195847","article-title":"Uric acid transporters hiding in the intestine","volume":"54","author":"Xu","year":"2016","journal-title":"Pharm Biol"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0036","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/heartjnl-2020-318060","article-title":"Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure","volume":"107","author":"Joshi","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0037","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0038","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.kint.2019.12.021","article-title":"Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0039","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41467-019-13690-5","article-title":"Genome-wide association and Mendelian randomization analysis provide insights into the pathogenesis of heart failure","volume":"11","author":"Shah","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0040","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/ng.3396","article-title":"A comprehensive 1000 genomes-based genome-wide association meta-analysis of coronary artery disease","volume":"47","author":"Nikpay","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0041","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41588-018-0058-3","article-title":"Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes","volume":"50","author":"Malik","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0042","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41588-018-0205-x","article-title":"Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits","volume":"50","author":"Evangelou","year":"2018","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0043","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/hmg\/ddy327","article-title":"Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry","volume":"28","author":"Pulit","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomization analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0045","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/s41588-019-0407-x","article-title":"A catalog of genetic loci associated with kidney function from analyses of a million individuals","volume":"51","author":"Wuttke","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2022.152058_bib0046","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1038\/s41467-018-04951-w","article-title":"Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes","volume":"9","author":"Xue","year":"2018","journal-title":"Nat Commun"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:10:00Z","timestamp":1758733800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":46,"alternative-id":["S0049017222001093"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152058","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose cotransporter 1 inhibition and gout: Mendelian randomisation study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152058"}}